Origin and molecular pathogenesis of ovarian high-grade serous carcinoma

Annals of Oncology

Volumn 24, Issue SUPPL.10, 2013, Pages

  Kurman, R J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; CA 125 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN;

ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CHROMOSOMAL INSTABILITY; CHROMOSOME ABERRATION; CLINICAL TRIAL (TOPIC); EPIDERMOID CYST; FALSE POSITIVE RESULT; GENE MUTATION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; MALIGNANT TRANSFORMATION; METAPLASIA; MOLECULAR GENETICS; MOLECULAR PATHOLOGY; OVARY CARCINOMA; OVULATION; PELVIS CANCER; PRIORITY JOURNAL; RISK REDUCTION; SALPINGECTOMY; SALPINGOOOPHORECTOMY; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TRANSVAGINAL ECHOGRAPHY; UTERINE TUBE CARCINOMA;

CARCINOMA; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; NEOPLASM GRADING; OVARIAN NEOPLASMS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84888213291     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt463     Document Type: Article

References (38)

1. Shih I, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004; 164: 1511-1518.
2. Kurman RJ, Shih I. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol 2011; 42: 918-931.
3. Wiegand KC, Shah SP, Al-Agha OM et al. ARID1A mutations in endometriosisassociated ovarian carcinomas. N Engl J Med 2010; 363: 1532-1543.
4. Piek JM, van Diest PJ, Zweemer RP et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001; 195: 451-456.
5. Gross AL, Kurman RJ, Vang R et al. Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics. J Oncol 2010; 2010: 126295.
6. Saleemuddin A, Folkins AK, Garrett L et al. Risk factors for a serous cancer precursor ('p53 signature') in women with inherited BRCA mutations. Gynecol Oncol 2008; 111: 226-232.
7. Crum CP, Drapkin R, Kindelberger D et al. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res 2007; 5: 35-44.
8. Callahan MJ, Crum CP, Medeiros F et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007; 25: 3985-3990.
9. Carcangiu ML, Radice P, Manoukian S et al. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Int J Gynecol Pathol 2004; 23: 35-40.
10. Medeiros F, Muto MG, Lee Y et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006; 30: 230-236.
11. Piek JM, Verheijen RH, Kenemans P et al. BRCA1/2-related ovarian cancers are of tubal origin: a hypothesis. Gynecol Oncol 2003; 90: 491.
12. Tone AA, Begley H, Sharma M et al. Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma. Clin Cancer Res 2008; 14: 4067-4078.
13. Kindelberger DW, Lee Y, Miron A et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007; 31: 161-169.
14. Przybycin CG, Kurman RJ, Ronnett BM et al. Are all pelvic (nonuterine) serous carcinomas of tubal origin?. Am. J. Surg Pathol 2010; 34: 1407-1416.
15. Kuhn E, Kurman RJ, Vang R et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J Pathol 2012; 226: 421-426.
16. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
17. Kuhn E, Meeker A, Wang TL et al. Shortened telomeres in serous tubal intraepithelial carcinoma. An early event in ovarian high-grade serous carcinognesis. Am J Surg Pathol 2010; 34: 829-836.
18. Kurman RJ, Shih I. The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. Am J Surg Pathol 2010; 34: 433-443.
19. Pothuri B, Leitao MM, Levine DA et al. Genetic analysis of the early natural history of epithelial ovarian carcinoma. PLoS One 2010; 5: e10358.
20. Lee Y, Miron A, Drapkin R et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007; 211: 26-35.
21. Jarboe E, Folkins A, Nucci MR et al. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol 2008; 27: 1-9.
22. Sehdev AS, Kurman RJ, Kuhn E et al. Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including rsf-1 (HBXAP), cyclin E and fatty acid synthase. Mod Pathol 2010; 23: 844-855.
23. Maeda D, Ota S, Takazawa Y et al. Mucosal carcinoma of the fallopian tube coexists with ovarian cancer of serous subtype only: a study of Japanese cases. Virchows Arch 2010; 457: 597-608.
24. Yemelyanova A, Vang R, Kshirsagar M et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol 2011; 24: 1248-1253.
25. Kuhn E, Kurman RJ, Sehdev AS et al. Ki-67 labeling index as an adjunct in the diagnosis of serous tubal intraepithelial carcinoma. Int J Gynecol Pathol 2012; 31: 416-422.
26. Longacre TA, Oliva E, Soslow RA. Association of Directors of Anatomic and Surgical Pathology. Recommendations for the reporting of fallopian tube neoplasms. Hum Pathol. 2007; 38: 1160-1163.
27. Fathalla MF. Incessant ovulation-a factor in ovarian neoplasia? Lancet 1971; 2: 163.
28. Risch HA, Weiss NS, Lyon JL et al. Events of reproductive life and the incidence of epithelial ovarian cancer. Am J Epidemiol 1983; 117: 128-139.
29. Song Z. Ovarian enzymatically active stromal cells can be a promoter of ovarian surface epithelial tumor. Med. Hypotheses. 2011; 77: 356-358.
30. Scully RE, Richardson GS. Luteinization of the stroma of metastatic cancer involving the ovary and its endocrine significance. Cancer 1961; 14: 827-840.
31. Rutgers JL, Scully RE. Functioning ovarian tumors with peripheral steroid cell proliferation: a report of twenty-four cases. Int J Gynecol Pathol 1986; 5: 319-337.
32. Malpica A, Deavers MT, Lu K et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004; 28: 496-504.
33. Dehari R, Kurman RJ, Logani S et al. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Am J Surg Pathol 2007; 31: 1007-1012.
34. Boyd C, Mccluggage WG. Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon. Am J Surg Pathol 2012; 36: 368-375.
35. Buys SS, Partridge E, Greene MH et al. Ovarian cancer screening in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 2005; 193: 1630-1639.
36. Buys SS, Partridge E, Black A et al. Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA 2011; 305: 2295-2303.
37. Kinde I, Bettegowda C, Wang Y et al. Evaluation of DNA from the papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 2013; 5: 167ra4.
38. Collaborative Group on Epidemiological Studies of Ovarian CancerBeral V, Doll R, Hermon C et al. Ovarian cancer and oral contraceptives: Collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371: 303-314.